Whitaker Uses Endowment to Advance Healing

Professor Evangelia Micheli-Tzanakou developed an experimental operation at Rutgers University that uses magnetic resonance imaging (MRI) and electrodes placed in the brain to reduce Parkinson's disease symptoms. Following surgery, patients walk and move without the usual unsteadiness that accompanies the disease. "The work is the most rewarding science I have done in my entire career," Micheli-Tzanakou says. The researcher also created the first computer-to-brain interface by combining computat

Written byJennifer Fisher Wilson
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The researcher also created the first computer-to-brain interface by combining computational intelligence with online brain activity recordings to analyze brain responses from humans and animals. To encourage scientists like Micheli-Tzanakou to advance healing technologies, the Whitaker Foundation, created in 1975, has focused its giving on biomedical engineering.

Inspired by Uncas A. Whitaker, an engineer and attorney who believed the marriage of medicine and engineering would bring advances in healing, the foundation has boosted its spending from $14 million to $60 to $70 million annually for a total of $575 million since 1992. Whitaker officials have staked the foundation's endowment to create jobs, advance teaching and research: they plan to close it in 2006 after spending nearly $1 billion on biomedical engineering.

Elsewhere, research in the field that originally helped pioneer open-heart surgery now includes bioengineered skin, timed-release drug capsules, artificial articulated joints, and artificial organs. At the University of Michigan, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies